SINYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

SHOULDER INNOVATIONS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$18.25+0.16 (+0.88%)

Close on Oct 19, 2026

Market cap: $378.43M
P/E (TTM): –
Dividend yield: –

SHOULDER INNOVATIONS, INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Cash & Equivalents	27	6.12	6.24
Short-Term Investments	97	8.92	–
Cash & Short-Term Investments	124	15	6.24
Receivables	8.27	5.12	–
Inventory	22	14	–
Prepaid Expenses & Other	1.52	0.43	–
Other Current Assets	1.48	0.57	–
Total Current Assets	157	35	–
Property, Plant & Equipment	13	7.49	–
Gross Property, Plant & Equipment	19	12	–
Accumulated Depreciation	-6.88	-4.24	–
Operating Lease Right-of-Use Assets	0.11	0.07	–
Intangible Assets	0.10	0.40	–
Other Long-Term Assets	0	–	–
Total Assets	170	43	–
Accounts Payable	8.87	4.86	–
Accrued Expenses	5.26	2.74	–
Current Portion of Leases	0.06	0.05	–
Total Current Liabilities	14	7.65	–
Long-Term Debt	15	15	–
Operating Lease Liabilities	0.11	0.05	–
Other Long-Term Liabilities	0.05	0.03	–
Total Liabilities	29	23	–
Total Debt	15	15	–
Preferred Stock	0	0	–
Common Stock	0.02	0.00	–
Additional Paid-In Capital	238	2.15	–
Retained Earnings	-97	-57	–
Comprehensive Income & Other	0.12	0.20	–
Shareholders' Equity	141	-55	-40
Total Equity	141	-55	-40
Total Liabilities & Equity	170	43	–
Shares Outstanding(shares)	21	0.08	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 77.3%
Operating margin: -58.5%
Net margin: -58.3%
Return on equity, FY2025: -93.8%

Financial strength

Current ratio: 10.71
Debt to equity: 0.12
Debt to assets: 9.7%
Cash to current liabilities: 190.6%

Valuation

P/E ratio: –
Price to sales: 6.30
Price to book: 3.04
Dividend yield: –